key: cord-1031471-dii5vezc
authors: Antinori, Spinello; Bonazzetti, Cecilia; Gubertini, Guido; Capetti, Amedeo; Pagani, Cristina; Morena, Valentina; Rimoldi, Sara; Galimberti, Laura; Sarzi-Puttini, Piercarlo; Ridolfo, Anna Lisa
title: Tocilizumab for cytokine storm syndrome in COVID-19 pneumonia: an increased risk for candidemia?
date: 2020-05-05
journal: Autoimmun Rev
DOI: 10.1016/j.autrev.2020.102564
sha: fdcca88cf956a181e841b08957cd2a92346f4ec3
doc_id: 1031471
cord_uid: dii5vezc

nan

We have read with interest the excellent review by McGonagle et al. discussing the possible role of hyperinflammation secondary to macrophage activation syndrome (MAS) or cytokine storm also known as secondary haemophagocitic lymphohistocytosis (sHLH) in the immunopathology of severe COVID-19 pneumonia. 1 High levels of interleukin-6 (IL-6) associated with poor outcome in the setting of COVID-19 pneumonia evoked the use of tocilizumab (an IL-6 receptor monoclonal blocking agent) approved for the treatment of rheumatoid arthritis in Japan (2008), Europe (2009) and USA (2010). [2] [3] [4] [5] The drug has been approved in China for COVID-19 pneumonia and elevated IL-6 (ChiCTR2000029765) and in Italy, following the outbreak that involved our country from February 21, it was extensively used off-label before the Italian Regulatory Agency of Drug (AIFA, Agenzia Italiana del Farmaco) approved a randomized, double-blind, placebo controlled study to evaluate the safety and efficacy of tocilizumab in patients with severe COVID-19 pneumonia (Tocilizumab 2020-001154-22).

Although an increased risk of infections, especially among patients treated with the 8 mg/kg of tocilizumab has been shown in a systematic literature review and meta-analysis as well as in a recently published registry of RA patients, a clear association with fungal infections has been not formally demonstrated. [6] [7] [8] During an eleven-days period (March 10 to March 18,2020) 43 patients with severe COVID-19 pneumonia were treated with tocilizumab at our Department (either in ICU and Infectious Diseases wards) and 3 patients (16,3%) developed candidaemia, one with endophthalmitis and endocarditis.

Interestingly, only one of the three patients (Table 1) 10, 11 In conclusion, we recommend to use selective cytokine blockade as well as JAK inhibitors for possible cytokine storm syndrome during COVID-19 pneumonia only in the context of welldesigned clinical trials. Moreover, since most of the inflammatory response (i.e., fever, high Creactive protein) can be blunted following such treatment an high index of suspicion for candidemia together with proactive surveillance should be deserved for these patients. 

Interleukin-6 use in COVID-19 pneumonia related macrophage activation syndrome

Risk factors associated with acute respiratory distress syndrome and death in patients with Coronavirus disease

The cytokine release syndrome (CRS) of severe COVID-19 and interleukin-6 receptor (IL-6R) antagonist Tocilizumab may be the key to reduce the mortality

IL-6 inhibitor for the treatment of rheumatoid arthritis: a comprehensive review

Risk of adverse events including serious infections in rheumatoid arthritis patients treated with tocilizumab: a systematic literature review and meta-analysis of randomized controlled trials

Risk factors of serious infections in patients with rheumatoid arthritis treated with tocilizumab in the French Registry Regate

Integrated safety in tocilizumab clinical trials

Candidemia and invasive candidiasis in adults: a narrative review

Impaired neutrophil response and CD+ T helper cell 1 development in interleukin-6-deficient mice infected with Candida albicans

Increased susceptibility to systemic candidiasis in interleukin-6 deficient mice